BR0102607A - Compostos de difeniluréia, um processo para sua preparação e composições farmacêuticas contendo os mesmos - Google Patents

Compostos de difeniluréia, um processo para sua preparação e composições farmacêuticas contendo os mesmos

Info

Publication number
BR0102607A
BR0102607A BR0102607-0A BR0102607A BR0102607A BR 0102607 A BR0102607 A BR 0102607A BR 0102607 A BR0102607 A BR 0102607A BR 0102607 A BR0102607 A BR 0102607A
Authority
BR
Brazil
Prior art keywords
optionally substituted
group
alkyl
atom
nitro
Prior art date
Application number
BR0102607-0A
Other languages
English (en)
Inventor
Gilbert Lavielle
Olivier Muller
Mark Millan
Anne Dekeyne
Mauricette Brocco
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Publication of BR0102607A publication Critical patent/BR0102607A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/201,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Patente de Invenção: "COMPOSTOS DE DIFENILURéIA, UM PROCESSO PARA SUA PREPARAçãO E COMPOSIçõES FARMACêUTICAS CONTENDO OS MESMOS". Compostos da fórmula (I): em que: R~ 1~, R~ 2~, R~ 3~ e R~ 4~ independentemente representam um átomo de hidrogênio, um átomo de halogeno ou um grupo alquila, alcóxi, hidróxi, ciano, amino opcionalmente substituído, nitro, carbóxi, alcoxicarbonila, aminocarbonila opcionalmente substituída ou carbamoíla, L~ 1~ e L~ 2~ cada um representa um átomo de hidrogênio ou juntos formam um grupo -CH~ 2~-CH~ 2~-, X~ 1~ ligado na posição 2 ou 3 do anel aromático, representa uma ligação, e no caso X~ 2~ representa um átomo de hidrogênio, um átomo de halogeno, ou um grupo alquila, alcóxi, hidróxi, nitro, ciano ou amino opcionalmente substituído, ou X~ 1~ e X~ 2~, juntos com os dois átomos de carbono adjacentes aos quais eles estão ligados na posição 2, 3 ou 4 do anel aromático, formam um grupo cicloalquila (C4-C7), em que um ou dois grupos -CH~ 2~- do anel cicloalquila são opcionalmente substituídos por um átomo de oxigênio ou um grupo NH, X~ 3~ representa um átomo de hidrogênio, um de halogeno, um grupo alquila, alcóxi, hidróxi, nitro, ciano ou amino opcionalmente substituído, G representa um grupo selecionado de: em que: as linhas pontilhadas indicam a presença opcional de uma ligação dupla, Alk representa um grupo alquileno (C1-C6) linear ou ramificado, n é 0 ou 1, T~ 3~ representa um grupo alquila, arila opcionalmente substituída, arilalquila opcionalmente substituída, heteroarila opcionalmente substituída ou heteroarilalquila opcionalmente substituída, T~ 4~ representa um grupo alquila, arila opcionalmente substituída, arilalquila opcionalmente substituída, heteroarila opcionalmente substituída ou heteroarilalquila opcionalmente substituída, Medicamentos.
BR0102607-0A 2000-06-29 2001-06-29 Compostos de difeniluréia, um processo para sua preparação e composições farmacêuticas contendo os mesmos BR0102607A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0008378A FR2810979B1 (fr) 2000-06-29 2000-06-29 Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
BR0102607A true BR0102607A (pt) 2002-05-28

Family

ID=8851854

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0102607-0A BR0102607A (pt) 2000-06-29 2001-06-29 Compostos de difeniluréia, um processo para sua preparação e composições farmacêuticas contendo os mesmos

Country Status (24)

Country Link
US (2) US6784183B2 (pt)
EP (1) EP1170288B9 (pt)
JP (1) JP3933889B2 (pt)
KR (1) KR100485018B1 (pt)
CN (1) CN1241916C (pt)
AR (1) AR033379A1 (pt)
AT (1) ATE273283T1 (pt)
AU (1) AU780022B2 (pt)
BR (1) BR0102607A (pt)
CA (1) CA2352405C (pt)
DE (1) DE60104776T2 (pt)
DK (1) DK1170288T3 (pt)
EA (1) EA005128B1 (pt)
ES (1) ES2227088T3 (pt)
FR (1) FR2810979B1 (pt)
HK (1) HK1042698B (pt)
HU (1) HUP0102723A3 (pt)
NO (1) NO320310B1 (pt)
NZ (1) NZ512658A (pt)
PL (1) PL348392A1 (pt)
PT (1) PT1170288E (pt)
SI (1) SI1170288T1 (pt)
TR (1) TR200402069T4 (pt)
ZA (1) ZA200105394B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
TW200306783A (en) * 2002-04-29 2003-12-01 Fmc Corp Pesticidal heterocycles
US20060229335A1 (en) * 2002-12-24 2006-10-12 Bradley Teegarden Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
US7319111B2 (en) * 2003-02-20 2008-01-15 Encysive Pharmaceuticals, Inc. Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists
PT1558582E (pt) * 2003-07-22 2006-05-31 Arena Pharm Inc Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
FR2859723B1 (fr) * 2003-09-16 2005-10-21 Servier Lab Nouveaux derives de benzoindoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1663960B1 (en) 2003-09-25 2011-08-24 Dompe' S.P.A. Amidines and derivatives thereof and pharmaceutical compositions containing them
CA2559038C (en) * 2004-03-23 2013-09-10 Arena Pharmaceuticals, Inc. Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl) phenyl] ureas and intermediates thereof
SA05260357B1 (ar) * 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
WO2006060762A2 (en) * 2004-12-03 2006-06-08 Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
WO2006076592A1 (en) 2005-01-14 2006-07-20 Cgi Pharmaceuticals, Inc. 1,3 substituted diaryl ureas as modulators of kinase activity
EP1843762A1 (en) * 2005-01-19 2007-10-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
JP5286254B2 (ja) 2006-05-18 2013-09-11 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−ht2aセロトニンレセプター活性のモジュレーターとして有用なフェニルピラゾールの結晶形態および調製方法
CA2646076C (en) 2006-05-18 2015-06-30 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
ES2536762T3 (es) 2006-05-18 2015-05-28 Arena Pharmaceuticals, Inc. Aminas primarias y sus derivados como moduladores del receptor de la serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con este
CN100390150C (zh) * 2006-06-05 2008-05-28 吴汝林 盐酸咪唑苯脲的制备方法
TWI415845B (zh) * 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
WO2008100480A1 (en) 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
MX2009008777A (es) * 2007-02-13 2009-08-25 Schering Corp Derivados y analogos de cromano como agonistas de los receptores alfa2c adrenergicos funcionalmente selectivos.
WO2009023253A2 (en) 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
CN104739829B (zh) 2008-10-28 2018-11-06 艾尼纳制药公司 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
RS57462B1 (sr) * 2013-03-15 2018-09-28 Bristol Myers Squibb Co Inhibitori indolamin 2,3-dioksigenaze (ido)
AR104882A1 (es) * 2015-06-05 2017-08-23 Orion Corp DERIVADOS DE 2-(1-HETEROARILPIPERAZIN-4-IL)METIL-1,4-BENZODIOXANO COMO ANTAGONISTAS DE a2C
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
PL248268B1 (pl) * 2023-04-13 2025-11-17 Univ Medyczny W Lublinie 1-(1-fenyloimidazolin-2-ylo)-3-aryloalkilo pochodne mocznika oraz sposób ich wytwarzania i ich zastosowanie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981000543A1 (en) * 1979-08-23 1981-03-05 Caterpillar Tractor Co Track assembly anti-torsion chains and method
GB9313913D0 (en) * 1993-07-06 1993-08-18 Smithkline Beecham Plc Novel compounds
US5905080A (en) * 1993-08-20 1999-05-18 Smithkline Beecham, P.L.C. Amide and urea derivatives as 5HT1D receptor antagonists
GB9420999D0 (en) * 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
JP2001508767A (ja) * 1996-12-02 2001-07-03 藤沢薬品工業株式会社 5―ht拮抗作用を有するインドール―ウレア誘導体
US6159979A (en) * 1997-04-18 2000-12-12 Smithkline Beecham P.L.C. Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity

Also Published As

Publication number Publication date
US20020025965A1 (en) 2002-02-28
US6784183B2 (en) 2004-08-31
SI1170288T1 (en) 2004-12-31
FR2810979A1 (fr) 2002-01-04
EP1170288B9 (fr) 2005-01-26
NO20013254D0 (no) 2001-06-28
EP1170288B1 (fr) 2004-08-11
AU5414401A (en) 2002-01-03
JP2002037778A (ja) 2002-02-06
HU0102723D0 (en) 2001-08-28
EA005128B1 (ru) 2004-12-30
DE60104776D1 (de) 2004-09-16
KR100485018B1 (ko) 2005-04-25
EP1170288A3 (fr) 2002-01-16
DE60104776T2 (de) 2005-09-01
HK1042698B (zh) 2006-08-11
NZ512658A (en) 2002-10-25
HK1042698A1 (en) 2002-08-23
HUP0102723A2 (hu) 2002-03-28
DK1170288T3 (da) 2004-11-29
AR033379A1 (es) 2003-12-17
NO320310B1 (no) 2005-11-21
ES2227088T3 (es) 2005-04-01
CA2352405A1 (fr) 2001-12-29
ZA200105394B (en) 2002-01-31
KR20020002249A (ko) 2002-01-09
CN1241916C (zh) 2006-02-15
EA200100600A2 (ru) 2002-02-28
AU780022B2 (en) 2005-02-24
PL348392A1 (en) 2002-01-02
JP3933889B2 (ja) 2007-06-20
PT1170288E (pt) 2004-10-29
HUP0102723A3 (en) 2002-11-28
EP1170288A2 (fr) 2002-01-09
US7026357B2 (en) 2006-04-11
CA2352405C (fr) 2006-10-03
CN1337395A (zh) 2002-02-27
TR200402069T4 (tr) 2004-09-21
US20040224993A1 (en) 2004-11-11
EA200100600A3 (ru) 2002-04-25
FR2810979B1 (fr) 2002-08-23
ATE273283T1 (de) 2004-08-15
NO20013254L (no) 2001-12-31

Similar Documents

Publication Publication Date Title
BR0102607A (pt) Compostos de difeniluréia, um processo para sua preparação e composições farmacêuticas contendo os mesmos
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
BR0209431A (pt) Novos compostos de 4-anilinoquinolino-3-carboxamidas
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
BRPI0409241A (pt) compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso
BR0313880A (pt) composto, pró-droga, composição farmacêutica, composição e método para modular receptor de cálcio, método para prevenir ou tratar doenças ósseas, e, uso do composto ou um sal deste ou uma pró-droga deste
BRPI0509795A (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso do composto ou sal farmacologicamente aceitável do mesmo, e, método para promover osteogênese, supressão de ressorção óssea e/ou melhoramento da densidade óssea
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
BR0308261A (pt) Métodos extrativos para puruficação de sucralose
BRPI0510453A (pt) composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0418255A (pt) derivados de piperazina e piperidina n-substituìdos
BRPI0410669A (pt) inibidores de caspase e usos dos mesmo
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
BRPI0417157A (pt) composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
AR027296A1 (es) Derivados de 4-heteroaril-1,4-diazabiciclo[3.2.2]nonano, su preparacion y su aplicacion terapeutica
BR0308419A (pt) Derivados de azetidina como antagonistas do receptor ccr-3
ATE482933T1 (de) Sulfopyrrolderivate
BR0315800A (pt) Derivados de imidazopiridina, seu processo de preparação e as composições farmacêuticas que os contêm
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
BR0100234A (pt) Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos
BRPI0411308A (pt) composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
EA200702375A1 (ru) Производные мочевины, способы их получения и применения

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: LES LABORATOIRES SERVIER (FR)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.